Silver Book Fact

t-PA cost savings

The total annual benefit to society from t-PA use in the United States is around $363 million—$60 million in direct cost savings to society plus an additional 7,510 QALYs. This means that t-PA saves $6,074 and adds 0.75 QALY per use.

Johnston S. The Economic Case for New Stroke Thrombolytics. Stroke. 2010; 41(10): S59-62. http://stroke.ahajournals.org/cgi/content/short/41/10_suppl_1/S59

Reference

Title
The Economic Case for New Stroke Thrombolytics
Publication
Stroke
Publication Date
2010
Authors
Johnston S
Volume & Issue
Volume 41, Issue 10
Pages
S59-62
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Catheter ablation reduces risk of stroke and death among AFib patients
    Atrial fibrillation patients who underwent catheter ablation had a reduced risk of stroke and death—2.2% of those who had ablation experienced stroke versus 4.7% on medications alone, and 6% died from…  
  • Stroke rates among Afib patients
    In one year, 58,283 of the 1.265 million Medicare beneficiaries with atrial fibrillation that did not receive prophylaxis suffered a stroke. For those who did receive anti-coagulants, 38,468 suffered strokes.  
  • t-PA cost savings
    The total annual benefit to society from t-PA use in the United States is around $363 million—$60 million in direct cost savings to society plus an additional 7,510 QALYs. This means…  
  • Adjusted-dose warfarin reduced stroke risk in AFib patients
    Meta-analysis of randomized trials found that adjusted-dose warfarin reduced stroke risk in atrial fibrillation patients by 60%. Antiplatelet agents reduced risk by 20%.  
  • Effectiveness of pacemaker/defibrillators to control AFib
    Widespread use of pacemaker/defibrillators to control atrial fibrillation could result in a 50% decrease in stroke.